Search results for "Neoplastic"

showing 10 items of 2901 documents

Contact-dependent inhibition of growth of normal diploid human fibroblasts by plasma membrane glycoproteins.

1988

Homeostasis in vivo is maintained by a highly complex network of positive and negative signals. At the cellular level, this regulatory microenvironment can be divided, in a simplified fashion, into two major compartments: the humoral compartment, including compounds such as hormones, growth factors and nutrients, and the contact-environment compartment, including cell-cell and cell-matrix interactions. At least in cultures of diploid, non-transformed cells, cell-cell and cell-matrix interactions have been shown to be of major importance for the regulation of growth as well as of differentiation. Although until now the glycoprotein involved in the contact-dependent inhibition of growth has n…

GlycanCell CommunicationPlatelet Membrane GlycoproteinsBiochemistrychemistry.chemical_compoundmedicineCompartment (development)AnimalsHumansReceptors ImmunologicFibroblastReceptorCells Culturedchemistry.chemical_classificationMembrane GlycoproteinsbiologyContact InhibitionCell MembraneAntibodies MonoclonalBiological activityGeneral MedicineFibroblastsMembrane glycoproteinsmedicine.anatomical_structureCell Transformation NeoplasticchemistryBiochemistryPlatelet Glycoprotein GPIb-IX Complexbiology.proteinGrowth inhibitionGlycolipidsGlycoproteinCell DivisionBiochimie
researchProduct

Cytotoxicity and chemosensitizing activity of amphiphilic poly(glycerol)-poly(alkylene oxide) block copolymers.

2014

All polymeric chemosensitizers proposed thus far have a linear poly(ethylene glycol) (PEG) hydrophilic block. To testify whether precisely this chemical structure and architecture of the hydrophilic block is a prerequisite for chemosensitization, we tested a series of novel block copolymers containing a hyperbranched polyglycerol segment as a hydrophilic block (PPO-NG copolymers) on multi-drug-resistant (MDR) tumor cells in culture. PPO-NG copolymers inhibited MDR of three cell lines, indicating that the linear PEG can be substituted for a hyperbranched polyglycerol block without loss of the polymers' chemosensitizing activity. The extent of MDR reversal increased with the polymers affinity…

GlycerolPolymers and PlasticsCell SurvivalPolymersBioengineeringAntineoplastic AgentsMicellePolyethylene GlycolsBiomaterialschemistry.chemical_compoundInhibitory Concentration 50Polymer chemistryAmphiphilePEG ratioMaterials ChemistryCopolymerHumansATP Binding Cassette Transporter Subfamily B Member 1CytotoxicityMicelleschemistry.chemical_classificationDrug SynergismPolymerPoloxamerDrug Resistance MultiplechemistryDoxorubicinDrug Resistance NeoplasmMCF-7 CellsDrug Screening Assays AntitumorK562 CellsEthylene glycolHydrophobic and Hydrophilic InteractionsBiomacromolecules
researchProduct

Renal Function at Two Years in Liver Transplant Patients Receiving Everolimus: Results of a Randomized, Multicenter Study

2013

In a 24-month prospective, randomized, multicenter, open-label study, de novo liver transplant patients were randomized at 30 days to everolimus (EVR) + Reduced tacrolimus (TAC; n = 245), TAC Control (n = 243) or TAC Elimination (n = 231). Randomization to TAC Elimination was stopped prematurely due to a significantly higher rate of treated biopsy-proven acute rejection (tBPAR). The incidence of the primary efficacy endpoint, composite efficacy failure rate of tBPAR, graft loss or death postrandomization was similar with EVR + Reduced TAC (10.3%) or TAC Control (12.5%) at month 24 (difference -2.2%, 97.5% confidence interval [CI] -8.8%, 4.4%). BPAR was less frequent in the EVR + Reduced TAC…

Graft RejectionMalemTOR inhibitormedicine.medical_treatmentMedizinLiver transplantationKidneylaw.inventionAntineoplastic AgentImmunosuppressive AgentRandomized controlled triallawImmunology and AllergySirolimuPharmacology (medical)Prospective StudiestacrolimusProspective cohort studyglomerular filtration rateIncidenceGraft SurvivalMiddle AgedEuropeEverolimuTreatment OutcomeFemaleImmunosuppressive Agentsmedicine.drugHumanAdultmTOR inhibitorsmedicine.medical_specialtyliver transplantation everolimusRandomizationAdolescentEverolimus glomerular filtration rate mTOR inhibitors renal function tacrolimusUrologyRenal functionAntineoplastic Agentschemical and pharmacologic phenomenaFollow-Up StudieYoung AdultmedicineHumansEverolimusAgedSirolimusTransplantationEverolimusDose-Response Relationship Drugbusiness.industryrenal functiontacrolimuSouth AmericaSurgeryLiver TransplantationTransplantationstomatognathic diseasesProspective StudieSirolimusNorth AmericabusinessFollow-Up Studies
researchProduct

Ruthenium-arene complexes bearing naphthyl-substituted 1,3-dioxoindan-2-carboxamides ligands for G-quadruplex DNA recognition.

2019

Quadruplex nucleic acids – DNA/RNA secondary structures formed in guanine rich sequences – proved to have key roles in the biology of cancers and, as such, in recent years they emerged as promising targets for small molecules. Many reports demonstrated that metal complexes can effectively stabilize quadruplex structures, promoting telomerase inhibition, downregulation of the expression of cancer-related genes and ultimately cancer cell death. Although extensively explored as anticancer agents, studies on the ability of ruthenium arene complexes to interact with quadruplex nucleic acids are surprisingly almost unknown. Herein, we report on the synthesis and characterization of four novel Ru(…

GuanineStereochemistryCell Survivalchemistry.chemical_elementAntineoplastic Agents010402 general chemistryG-quadruplexLigands01 natural sciencesRutheniumInorganic Chemistrychemistry.chemical_compoundStructure-Activity RelationshipCoordination ComplexesPyridineTumor Cells CulturedHumansRuthenium Quadruplex G-quadruplex G4 DNA Cancer Metal Complexesheterocyclic compoundsCell ProliferationDose-Response Relationship DrugMolecular Structure010405 organic chemistryLigandRNASmall molecule3. Good health0104 chemical sciencesRutheniumG-QuadruplexeschemistrySettore CHIM/03 - Chimica Generale E InorganicaCalixarenesDrug Screening Assays AntitumorDNADalton transactions (Cambridge, England : 2003)
researchProduct

Triterpenoid saponins from the roots of two Gypsophila species.

2013

Two triterpenoid saponins with two known ones have been isolated from the roots of Gypsophila arrostii var. nebulosa, and two new ones from the roots of Gypsophila bicolor. Their structures were established by extensive NMR and mass spectroscopic techniques as 3-O-β-d-galactopyranosyl-(1→2)-[β-d-xylopyranosyl-(1→3)]-β-d-glucuronopyranosylquillaic acid 28-O-β-d-xylopyranosyl-(1→4)-[β-d-glucopyranosyl-(1→3)]-α-l-rhamnopyranosyl-(1→2)-[β-d-glucopyranosyl-(1→4)]-β-d-fucopyranosyl ester (1), 3-O-β-d-galactopyranosyl-(1→2)-[β-d-xylopyranosyl-(1→3)]-β-d-glucuronopyranosylgypsogenin 28-O-β-d-xylopyranosyl-(1→4)-[β-d-glucopyranosyl-(1→3)]-α-l-rhamnopyranosyl-(1→2)-[β-d-glucopyranosyl-(1→4)]-β-d-fuco…

Gypsophila arrostiiGypsophilaStereochemistryCell SurvivalMolecular ConformationStereoisomerismAntineoplastic AgentsCaryophyllaceaePlant ScienceHorticultureBiochemistryPlant RootsCell LineTerpeneStructure-Activity RelationshipTriterpenoidSpecies SpecificityAnimalsHumansMolecular BiologyCell ProliferationPlant rootsbiologyDose-Response Relationship DrugChemistryStereoisomerismGeneral MedicineSaponinsbiology.organism_classificationTriterpenesRatsHuman colon cancerDrug Screening Assays AntitumorTwo-dimensional nuclear magnetic resonance spectroscopyPhytochemistry
researchProduct

Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein

2008

To evaluate the synergistic targeting and killing of human hepatocellular carcinoma (HCC) cells lacking p53 by the oncolytic autonomous parvovirus (PV) H-1 and chemotherapeutic agents and its dependence on functional promyelocytic leukemia protein (PML).The role of p53 and PML in regulating cytotoxicity and gene transfer mediated by wild-type (wt) PV H-1 were explored in two pairs of isogenic human hepatoma cell lines with different p53 status. Furthermore, H-1 PV infection was combined with cytostatic drug treatment.While the HCC cells with different p53 status studied were all susceptible to H-1 PV-induced apoptosis, the cytotoxicity of H-1 PV was more pronounced in p53-negative than in p…

H-1 parvovirusLiver CancerH-1 parvovirusCarcinoma HepatocellularParvovirus H-1virusesAntineoplastic AgentsApoptosisPromyelocytic Leukemia ProteinPromyelocytic leukemia proteinDrug TherapyCell Line TumorHumansNuclear proteinCytotoxicityMembrane Potential MitochondrialbiologyParvovirusTumor Suppressor ProteinsLiver NeoplasmsGastroenterologyvirus diseasesNuclear ProteinsGeneral Medicinebiology.organism_classificationCombined Modality Therapydigestive system diseasesOncolytic virusApoptosisCancer researchbiology.proteinFluorouracilCisplatinTumor Suppressor Protein p53Transcription FactorsWorld Journal of Gastroenterology
researchProduct

Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage

2020

International audience; Intestinal microbiota have been proposed to induce commensal-specific memory T cells that cross-react with tumor-associated antigens. We identified major histocompatibility complex (MHC) class I-binding epitopes in the tail length tape measure protein (TMP) of a prophage found in the genome of the bacteriophage Enterococcus hirae Mice bearing E. hirae harboring this prophage mounted a TMP-specific H-2Kb-restricted CD8+ T lymphocyte response upon immunotherapy with cyclophosphamide or anti-PD-1 antibodies. Administration of bacterial strains engineered to express the TMP epitope improved immunotherapy in mice. In renal and lung cancer patients, the presence of the ent…

H-2 AntigenProgrammed Cell Death 1 ReceptorCD8-Positive T-LymphocytesEpitopeEpitopesFecesMice0302 clinical medicineEnterococcus hiraeNeoplasmsMonoclonalBacteriophages0303 health sciencesMultidisciplinarybiologyAntibodies MonoclonalViral Tail ProteinsAlkylating3. Good healthmedicine.anatomical_structure030220 oncology & carcinogenesisCross ReactionEpitopeImmunotherapyHumanT cellAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/CancerCross ReactionsMajor histocompatibility complexAntibodiesMicrobiology03 medical and health sciencesAnimals; Antibodies Monoclonal; Antigens Neoplasm; Antineoplastic Agents Alkylating; Bacteriophages; CD8-Positive T-Lymphocytes; Cross Reactions; Cyclophosphamide; Enterococcus hirae; Epitopes; Feces; Gastrointestinal Microbiome; H-2 Antigens; Histocompatibility Antigens Class I; Humans; Immunotherapy; Mice; Neoplasms; Programmed Cell Death 1 Receptor; Viral Tail Proteins[SDV.CAN] Life Sciences [q-bio]/CancerAntigenAntigens NeoplasmMHC class ImedicineAnimalsHumansAntigensBacteriophageAntineoplastic Agents AlkylatingCyclophosphamideProphage030304 developmental biologyEnterococcus hiraeAnimalHistocompatibility Antigens Class IH-2 AntigensCD8-Positive T-Lymphocytebiology.organism_classificationGastrointestinal Microbiomebiology.proteinNeoplasmFeceCD8
researchProduct

Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)

2021

Purpose: The most appropriate therapy for HR + /HER2-positive (HER2 +) advanced breast cancer (ABC) is a matter of debate. Co-targeting of both receptors represents an attractive strategy to overcome the cross-talk between them. Methods: The HERMIONE 9 is an observational retrospective multicentric study which aimed to describe the clinical outcome of patients with HR + /HER2 + ABC who received the combination of Fulvestrant (F) and Trastuzumab (T) as part of their routine treatment at 10 Italian Institutions. Results: Eighty-seven patients were included. Median age was 63 (range, 35–87) years. The median number of previous treatments was 3 (range, 0–10) and F and T were administered as ≥ 3…

HER2 positiveOncologyCancer Researchmedicine.medical_specialtySettore MED/06 - Oncologia MedicaReceptor ErbB-2Advanced breastBreast NeoplasmsBreast cancerMaintenance therapyTrastuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansFulvestrantRetrospective StudiesHormone receptor positiveFulvestrantbusiness.industryCancerMiddle AgedTrastuzumabmedicine.diseaseItalyOncologyCohortAdvanced breast cancerFemalePertuzumabbusinessmedicine.drugBreast Cancer Research and Treatment
researchProduct

Precision medicine in breast cancer: reality or utopia?

2017

International audience; Many cancers, including breast cancer, have demonstrated prognosis and support advantages thanks to the discovery of targeted therapies. The advent of these new approaches marked the rise of precision medicine, which leads to improve the diagnosis, prognosis and treatment of cancer. Precision medicine takes into account the molecular and biological specificities of the patient and their tumors that will influence the treatment determined by physicians. This new era of medicine is accessible through molecular genetics platforms, the development of high-speed sequencers and means of analysis of these data. Despite the spectacular results in the treatment of cancers inc…

HER2+0301 basic medicineTumor heterogeneitymedicine.medical_specialtyPathologyMolecular subtypeslcsh:MedicineBreast NeoplasmsReviewCancer VaccinesTumor heterogeneityGeneral Biochemistry Genetics and Molecular BiologyGenetic Heterogeneity03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancer[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyHumansChemotherapyMedicineMedical physicsTriple negativebusiness.industrylcsh:RPrecision medicineCancerGeneral MedicinePrecision medicinemedicine.disease3. Good health030104 developmental biology030220 oncology & carcinogenesisNeoplastic Stem CellsTriple-negativeFemaleImmunotherapyPhase III clinical trialsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyJournal of Translational Medicine
researchProduct

Direct chemical grafted curcumin on halloysite nanotubes as dual-responsive prodrug for pharmacological applications

2016

Covalently functionalized halloysite nanotubes (HNTs) were successfully employed as dual-responsive nanocarriers for curcumin (Cur). Particularly, we synthesized HNT-Cur prodrug with a controlled curcumin release on dependence of both intracellular glutathione (GSH) and pH conditions. In order to obtain HNT-Cur produgs, halloysite was firstly functionalized with cysteamine through disulphide linkage. Afterwards, curcumin molecules were chemically conjugated to the amino end groups of halloysite via Schiff's base formation. The successful functionalization of halloysite was proved by thermogravimetric analysis, FT-IR spectroscopy, dynamic light scattering and scanning electron microscopy. Ex…

Halloysite nanotubeAntiproliferative activity02 engineering and technology01 natural scienceshalloysite nanotubes covalent functionalization curcumin prodrugchemistry.chemical_compoundColloid and Surface ChemistryOrganic chemistryProdrugsProdrugSettore CHIM/02 - Chimica FisicaDrug CarriersNanotubesChemistryAntioxidant propertieFree Radical ScavengersSurfaces and InterfacesGeneral MedicineProdrug021001 nanoscience & nanotechnologyDrug deliveryAluminum Silicates0210 nano-technologyDrug carrierOxidation-ReductionBiotechnologyCurcuminCell SurvivalAntineoplastic AgentsHalloysite nanotubes Curcumin Prodrug Antiproliferative activity Antioxidant propertiesengineering.materialConjugated system010402 general chemistryHalloysiteCell Line TumorHumansPhysical and Theoretical ChemistryCell ProliferationSettore CHIM/06 - Chimica OrganicaCombinatorial chemistry0104 chemical sciencesKineticsMicroscopy Electron ScanningengineeringCurcuminSettore BIO/14 - FarmacologiaClayPharmaceuticsNanocarriers
researchProduct